Platelet shape change (PSC) is an early phase of platelet activation that precedes platelet aggregation. This phase of platelet activation is essentially aspirin resistant. PSC was monitored, by measuring the median platelet volume (MPV) using a high resolution channelyser. Angiotensin (Ang) II, added in vitro, caused a significant (P ‫؍‬ 0.004) increase in MPV in platelet rich plasma prepared from healthy subjects (n ‫؍‬ 14). This increase in MPV was marked (Ͼ0.40 fl) in 57% (n ‫؍‬ 8) of these subjects and was significantly inhibited (P Ͻ 0.008) by losartan (a selective Ang II antagonist) at con-
Introduction
Angiotensin II (Ang II) is a peptide hormone that mediates its effects through binding to specific receptors; two receptor subtypes are recognised: subtype 1 (AT 1 ) and subtype 2 (AT 2 ). Ang II is one of several mediators that influence blood pressure. [1] [2] [3] [4] [5] Human platelets have Ang II receptors (AT 1 ) and this hormone is known to activate platelets. 6 However, Ang II has not previously been shown to induce platelet shape change (PSC), an early phase of platelet activation, which may be associated with the release of intra-platelet growth factors. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Inhibiting PSC is important because this is an aspirin-resistant phase of platelet activation. 7, 9 Losartan, is an effective and well-tolerated antihypertensive and is a specific competitive antagonist of AT 1 receptors. [2] [3] [4] [5] It would be an advantage if losartan had platelet inhibitory action since patients taking this antihypertensive drug are likely to be at risk of thrombotic disease. [2] [3] [4] [5] The purpose of the present study was to assess the stimulatory effect of Ang II on human PSC. We also assessed the capacity of losartan to inhibit PSC induced by a thromboxane A 2 (TXA 2 ) analogue. TXA 2 is both a potent platelet-aggregating agent and a vasoconstrictor. 15, 17 In addition, we evaluated the capacity of Ang II to enhance sub-maximal PSC induced by other agonists, ADP and serotonin (5-hydroxytryptamine; 5-HT). These agonists are relevant because they are released by activated platelets.
15,18-25 5-HT has also been implicated in platelet activation, vasoconstriction and smooth muscle proliferation.
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Materials and methods
Volunteers, sample collection and induction of PSC
Venous blood was collected in 3.8% citrate (1 part citrate to 9 parts blood) from 14 healthy (eight male and six female, with a median age of 32 years, range: 26-57), volunteers who denied taking any drugs for at least 2 weeks prior to sampling. The citrated blood was centrifuged at 160 g for 15 min at room temperature. Platelet rich plasma (PRP) was then carefully collected with a Pasteur pipette. Aliquots of PRP (450 l), in siliconised glass cuvettes, were placed in a Chronology dual channel optical aggregometer (Coulter Electronics, Luton, Beds, UK) and kept at 37°C for 15 min (without stirring) prior to the start of the experiments.
At specific times (shown in the results section below) after adding vehicle, drugs or agonists, the PRP was stirred (using a Teflon-coated metal stir bar) at 1000 rpm. Aliquots of PRP (100 l) were removed and mixed with 400 l of fixative (4% Journal of Human Hypertension aqueous glutaraldehyde). These sampling times were determined in previous studies. [7] [8] [9] [10] 13, 14, 16, 19 They represent the time when a maximal increase in median platelet volume (MPV) is observed for each agonist. This sample was further diluted 400-fold in Isoton II (Coulter Electronics).
A Coulter counter ZM 34 (electrical impedance method using a 70 m diameter sampling tube orifice) coupled to a Coulter C-256 high resolution (0.07 fl) channelyser (Coulter Electronics) was used to measure MPV in these samples. The analyser sample 'window' was set between 2.67 and 19.12 fl. [7] [8] [9] [10] 13, 14, 16, 19 Data were accumulated to a maximum of 500 platelets in one of the 256 channels. The MPV was the volume (in fl) of the channel on each side of which 50% of the platelet population was distributed. All MPV values are the average of three readings. In our hands, the intra-assay and inter-assay coefficient of variation for MPV measurement is 0.8% and 2.9%, respectively. The counter-channelyser system was calibrated using platelet latex particles (9 fl; Coulter Electronics). The platelet count was monitored to ensure that significant aggregation did not occur. The fall in platelet count was not greater than 5% in any of the samples included in this study.
Effect of Ang II on PSC
Ang II (0.5 ng/ml) or saline was added to PRP and incubated with stirring. Aliquots were removed to assess the MPV at various time points (5, 10 and 15 min). Most maximal responses were at 5 or 10 min. The increase in MPV was marked (Ͼ0.40 fl) in 57% (n ϭ 8) of these subjects. These subjects were used to assess the effect of losartan on Ang IIinduced PSC (see below).
Effect of losartan on Ang II-induced PSC
Losartan (2 g/ml; similar to therapeutic levels [2] [3] [4] [5] ) or vehicle (saline), was incubated for 5 min with PRP. Ang II (0.5 ng/ml) was then added to this PRP and aliquots were removed to assess the MPV after 10 min.
Enhancement of ADP-and 5-HT-induced PSC by Ang II
Saline, ADP (0.02-0.2 M/L) or 5-HT (0.03-0.12 M/L) was added to PRP and stirred for 3 min to assess the MPV. This process was repeated, but PRP was stimulated with a combination of Ang II (0.25-0.5 ng/ml) plus 5-HT or ADP. The agonist concentrations were selected to produce sub-maximal responses so as to allow the demonstration of enhancement.
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Effect of losartan on U46619 (a thromboxane A 2 analogue)-induced PSC Saline or U46619 (a thromboxane A 2 analogue, 0.03-0.05 M/L) was added to PRP and stirred, aliquots were removed at 3 min, to measure the MPV. Losartan (2 g/ml) or vehicle was incubated with PRP for 5 min (without stirring) before adding U46619 to assess the MPV at the same time point as before. The U46619 concentrations were selected to produce sub-maximal responses.
Effect of indomethacin on Ang II-induced increase in MPV
Previous work 7, 9 has indicated that the increase in MPV induced by several agonists (eg, ADP, 5HT, U46619) is aspirin resistant. We assessed the effect of indomethacin (INDO; 16 M/L) on Ang II (0.5 ng/ml)-induced increase in MPV.
In contrast to all the other agonists we investigated, the increase in MPV induced by arachidonic acid (AA; the substrate for eicosanoid synthesis, including thromboxane A 2 ) is aspirin sensitive. 7, 9 We used this property to assess the potency of INDO.
17 PRP was stimulated with AA (0.15 mmol/l) and the MPV was measured after 30 s. This was repeated after 5 min incubation with INDO (16 M/L).
Statistical analysis and presentation of results
The results are presented as median and interquartile range. Statistical comparisons are by non-parametric tests (paired Wilcoxon rank sum; two-tailed). We also considered statistical significance in the context of multiple comparisons using the 'Bonferroni' correction. To account for these multiple comparisons, we carried out a two-way ANOVA analysis where appropriate. (Table 1) Ang II (0.5 ng/ml) induced a significant (n ϭ 14; P ϭ 0.004 by two-way ANOVA) increase in MPV. The PSC response to Ang II was marked (a median increase of Ͼ0.40 fl in MPV) in 57% (n ϭ 8) of the subjects. (Table 2) In the group of Ang II responders (n ϭ 8 or 57% of subjects), losartan (2 g/ml; a concentration similar to therapeutic levels [2] [3] [4] [5] ) significantly (P Ͻ 0.008 at Statistical analysis: n = 14. Saline vs Ang II, 5 min P = NS*; Saline vs Ang II, 10 min P = 0.02*; Saline vs Ang II, 15 min P = 0.012*. *Because of multiple (three) comparisons, the level of significance for each sampling point is 0.05/3 = 0.017. To take account of these comparisons we carried out an ANOVA analysis (P = 0.004). 10 and 15 min) inhibited the Ang II-induced increase in MPV. The MPV in the saline control and in the Ang II + losartan samples did not differ significantly.
Results
Effect of Ang II on MPV
Effect of losartan on Ang II-induced PSC
Enhancement of ADP-and 5-HT-induced PSC by
Ang II (Table 3) In nine subjects (Ang II responders and nonresponders), Ang II significantly enhanced submaximal PSC induced by ADP and 5-HT. Because Ang II + ADP is also compared with both ADP only and Ang II only, the level of significance is 0.05/2 ϭ 0.025. This level was achieved ( Table 3) . The same argument applies to Ang II + 5-HT.
Effect of losartan on U46619 (a thromboxane A 2 analogue)-induced PSC
Losartan significantly inhibited (n ϭ 9; P Ͻ 0.001) U46619-stimulated PSC; saline alone ϭ 5.48 (5.26-5.99); U46619 alone ϭ 6.35 (6.25-6.37), and losartan + U46619 ϭ 6.04 (5.67-6.25).
Effect of indomethacin on Ang II-induced increase in MPV
The Ang II-induced increase in MPV (n ϭ 2) was not affected by indomethacin: saline ϭ 5.61, Ang II ϭ 5.85, INDO + Ang II 5.84 (fl).
The potency of the INDO solution was verified, by 
Discussion
We used PSC to show that Ang II activates platelets obtained from healthy subjects. This technique may be a more sensitive method than platelet aggregation to assess platelet activation. [7] [8] [9] [10] [11] [12] [13] [14] [15] 18, 19, 21 Thus, others using platelet aggregation did not detect the activating effect of Ang II on human platelets. 5 It is not clear why some subjects reacted more markedly to Ang II than others. It may be that responsiveness to Ang II varies in different individuals or disease states. For example, there is evidence of an increased effect of Ang II on platelet-free calcium concentrations and intracellular pH in untreated hypertensives. 6 Other studies showed that there was an upregulation of AT 1 receptor mRNA in platelets of patients with primary aldosteronism and renovascular hypertension. 26 The number of Ang II binding sites also differs in the platelets of pregnant women with and without hypertension. 27, 28 Ang II enhanced PSC induced by ADP and 5-HT. This is important since these agonist are released from activated platelets. 15, [18] [19] [20] [21] [22] [23] [24] [25] In this context, it is also relevant that the enhancement of thrombininduced platelet aggregation by Ang II has been reported by others. 6 Losartan, at levels similar to those achieved during treatment, [2] [3] [4] [5] inhibited the stimulatory effect of Ang II on human platelets despite the use of high concentrations 29 of Ang II (in vivo ϭ 10-60 ng/L; in vitro, in our study ϭ 0.25-0.5 g/L).
Losartan significantly inhibited U46619-induced PSC. This effect could be due to the imidazole ring in the losartan molecule. 4, 5 Others have also shown that losartan inhibited U46619-induced platelet aggregation and that this drug is a weak competitive antagonist of human platelet TXA 2 /prostaglandin H 2 receptors. 4, 5 These effects may be an advantage in patients not taking aspirin. However, even in those taking aspirin, the inhibition of TXA 2 synthesis may not be complete and losartan may eliminate any residual stimulatory effect of TXA 2 on human platelets. It is also relevant that TXA 2 can amplify the aggregatory response of other agonists like ADP. 5 We did not evaluate the effect of the main metabolite of losartan, EXP 3174. However, others have shown that this metabolite acts in a manner similar to the parent compound, losartan, in terms of Ang II and TXA 2 blockade. 5 The inhibitory effect of losartan on Ang II-and TXA 2 -induced PSC is of potential clinical relevance since patients taking losartan are likely to be at risk of thrombotic disease (eg, myocardial infarction). Furthermore, PSC is a phase of platelet activation that is essentially aspirin-resistant. 7, 9 This additional activity may confer an antithrombotic potential on this antihypertensive drug.
Our results suggest that losartan may have an antithrombotic effect as well as a blood pressure lowering effect. Other Ang II receptor blockers or antihypertensive drugs may not share the 'specific' TXA 2 -inhibiting property of losartan if their struc-ture does not include an imidazole group. The additional anti-thrombotic properties of antihypertensive drug [30] [31] [32] [33] [34] [35] may influence prescribing habits. Platelet responses to Ang II may reflect the changes occurring in other tissues. Therefore, these cells may represent an accessible model to assess the role of Ang II and Ang II antagonists in clinical studies.
The preliminary findings of this study were presented 10 at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting (ASPET) 1997, San Diego, California.
